In an interview about the efficacy of COVID-19 vaccines, Richard Marlink, the director of Rutgers Global Health Institute, responds to public opinion about the differences among vaccines that are authorized or in the pipeline for use in the United States. The following is an excerpt from the story published by ROI-NJ: When the news that Johnson & Johnson had completed Phase 3 of its clinical trial and that its one-shot vaccine would soon be available finally was released Friday morning, there was unbridled excitement. It would be a game-changer, many said. To read the full story.
Recent Posts
- NJ joins lawsuit against Trump over cuts to medical research that would hit Rutgers.
- Simulation Training: A Powerful Tool to Bridge Theory and Practice.
- New NJACTS Publication
- NJIT Maintains Highest Research Classification, Renews its R1 Status from Carnegie.
- Researchers Track Sharp Increase in Diagnoses for Sedative, Hypnotic and Anxiety Use Disorder in Young Adults.
Categories
- Community (2,137)
- Covid (981)
- CTO Events (6)
- News (2,727)
- Pilots (21)